PROTOKINETIX, INCORPORATED
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
(Unaudited)
For the Nine Months Ended September 30, 2017 and 2016
|
|
Nine Months ended
September 30, 2017
|
|
|
Nine Months ended
September 30, 2016
|
|
|
|
|
|
|
|
|
CASH FLOWS USED IN OPERATING ACTIVITIES
|
|
|
|
|
|
|
Net loss for the period
|
|
$
|
(1,006,051
|
)
|
|
$
|
(1,149,885
|
)
|
Adjustments to reconcile net loss to cash used in operating activities:
|
|
|
|
|
|
|
|
|
Amortization – intangible assets
|
|
|
2,250
|
|
|
|
2,250
|
|
Issuance and amortization of common stock for services
|
|
|
-
|
|
|
|
7,000
|
|
Fair value of compensatory options granted
|
|
|
587,077
|
|
|
|
574,128
|
|
|
|
|
|
|
|
|
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
-
|
|
|
|
8,023
|
|
Prepaid expenses and deposits
|
|
|
(42,953
|
)
|
|
|
(91,032
|
)
|
Accounts payable and accrued liabilities
|
|
|
(25,034
|
)
|
|
|
(5,002
|
)
|
|
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(484,711
|
)
|
|
|
(654,518
|
)
|
|
|
|
|
|
|
|
|
|
CASH FLOWS USED IN INVESTING ACTIVITIES
|
|
|
|
|
|
|
|
|
Purchase of intangible assets
|
|
|
(40,176
|
)
|
|
|
(7,589
|
)
|
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(40,176
|
)
|
|
|
(7,589
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES
|
|
|
|
|
|
|
|
|
Issuance of common stock for cash
|
|
|
540,000
|
|
|
|
380,000
|
|
|
|
|
|
|
|
|
|
|
Net cash from financing activities
|
|
|
540,000
|
|
|
|
380,000
|
|
|
|
|
|
|
|
|
|
|
Net change in cash
|
|
|
15,113
|
|
|
|
(282,107
|
)
|
|
|
|
|
|
|
|
|
|
Cash, beginning of period
|
|
|
371,029
|
|
|
|
371,072
|
|
|
|
|
|
|
|
|
|
|
Cash, end of period
|
|
$
|
386,142
|
|
|
$
|
88,965
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
|
|
|
|
|
|
|
Cash paid for income taxes
|
|
$
|
-
|
|
|
$
|
-
|
|
Supplementary information – non-cash transactions:
|
|
|
|
|
|
|
|
|
Common stock issued for consulting services
|
|
$
|
-
|
|
|
$
|
7,000
|
|
Intangible asset costs previously included in accounts payable and accrued liabilities
|
|
|
3,631
|
|
|
|
-
|
|
Intangible asset costs previously included in prepaid expenses and deposits
|
|
|
15,614
|
|
|
|
-
|
|
Intangible asset costs included in accounts payable and accrued liabilities
|
|
|
3,188
|
|
|
|
-
|
|
See Notes to Financial Statements
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 1. Basis of Presentation – Going Concern Uncertainties
ProtoKinetix, Incorporated (the “Company”), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. The Company is a medical research company whose mission is the advancement of human health care.
The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins (“AFGP”) or anti-aging glycoproteins, trademarked AAGP™. During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 4).
During the year ended December 31, 2016, the Company filed Form 51-105F1 – Notice – OTC Issuer Ceases to be an OTC Reporting Issuer with the British Columbia Securities Commission.
The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.
The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at September 30, 2017. These factors raise substantial doubt about the Company's ability to continue as a going concern.
The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective. Management is presently engaged in seeking additional working capital through equity financing or related party loans.
The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.
Note 2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K, filed February 21, 2017, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 2. Summary of Significant Accounting Policies
(cont’d)
Use of Estimates
Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.
Cash
Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.
Fair Value of Financial Instruments
Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:
Level 1 – quoted prices in active markets for identical assets or liabilities
Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable
Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
Level 1 inputs are used to measure cash. At September 30, 2017 there were no other assets or liabilities subject to additional disclosure.
Income Taxes
The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 2. Summary of Significant Accounting Policies
(cont’d)
Intangible Assets – Patent and Patent Application Costs
The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.
As at September 30, 2017, the Company does not hold any intangible assets with indefinite lives.
Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.
Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.
Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the patent application costs as at September 30, 2017.
Research and Development Costs
Research and development costs are expensed as incurred.
Loss per Share and Potentially Dilutive Securities
Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 55,100,000 stock options (September 30, 2016 – 28,600,000) and 6,500,000 warrants (September 30, 2016 – 6,500,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.
Share-Based Compensation
The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.
The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance.
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 2. Summary of Significant Accounting Policies
(cont’d)
Share-Based Compensation
(cont’d)
The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.
Common Stock
Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete.
Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.
Related Party Transactions
A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.
Recent Accounting Pronouncements
In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance did not have a material impact on the Company’s financial statements.
Accounting Standards Update 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy was effective for periods ending after December 16, 2016.
The adoption of this guidance did not have a material impact on the Company’s financial statements.
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 2. Summary of Significant Accounting Policies
(cont’d)
Recent Accounting Pronouncements
(cont’d)
Accounting Standards Update 2016-09 – Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect for periods ending after December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows.
The adoption of this guidance did not have a material impact on the Company’s financial statements.
Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements.
Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.
Note 3. Prepaid Expenses and Deposits
The following summarizes the Company’s prepaid expenses and deposits outstanding as at September 30, 2017 and December 31, 2016:
|
|
September 30, 2017
|
|
|
December 31, 2016
|
|
|
|
|
|
|
|
|
Deposit on research agreement (Note 11(c))
|
|
$
|
97,723
|
|
|
$
|
54,770
|
|
Other prepaid expenses
|
|
|
-
|
|
|
|
15,614
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
97,723
|
|
|
$
|
70,384
|
|
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 4.
Intangible Assets
Intangible asset transactions are summarized as follows:
|
|
Patent Rights
|
|
|
Patent Application
Rights
|
|
|
Total
|
|
Cost
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2015
|
|
$
|
30,000
|
|
|
$
|
41,760
|
|
|
$
|
71,760
|
|
Additions
|
|
|
-
|
|
|
|
33,421
|
|
|
|
33,421
|
|
Balance, December 31, 2016
|
|
$
|
30,000
|
|
|
$
|
75,181
|
|
|
$
|
105,181
|
|
Additions
|
|
|
-
|
|
|
|
55,347
|
|
|
|
55,347
|
|
Balance, September 30, 2017
|
|
$
|
30,000
|
|
|
$
|
130,528
|
|
|
$
|
160,528
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2015
|
|
$
|
1,500
|
|
|
$
|
-
|
|
|
$
|
1,500
|
|
Amortization
|
|
|
3,000
|
|
|
|
-
|
|
|
|
3,000
|
|
Balance, December 31, 2016
|
|
$
|
4,500
|
|
|
$
|
-
|
|
|
$
|
4,500
|
|
Amortization
|
|
|
2,250
|
|
|
|
-
|
|
|
|
2,250
|
|
Balance, September 30, 2017
|
|
$
|
6,750
|
|
|
$
|
-
|
|
|
$
|
6,750
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net carrying amounts
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2016
|
|
$
|
25,500
|
|
|
$
|
75,181
|
|
|
$
|
100,681
|
|
September 30, 2017
|
|
$
|
23,250
|
|
|
$
|
130,528
|
|
|
$
|
153,778
|
|
During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the “Patent Assignment”) with the Institut National des Sciences Appliquees de Rouen (“INSA”) for the assignment of certain patents and all rights associated therewith (the “Patents”). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the nine month period ended September 30, 2017, the Company recorded $2,250 (September 30, 2016 - $2,250) in amortization expense associated with the Patents.
During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the “Patent Application Rights”). In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company has incurred $82,047 in direct costs relating to the Patent Application Rights, $44,277 of which were incurred during the nine month period ended September 30, 2017.
The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty.
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 4.
Intangible Assets
(cont’d)
During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells” (the “New Patent Application Rights”). In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid). The Company has incurred $13,481 in direct costs relating to the New Patent Application Rights, $11,065 of which were incurred during the nine month period ended September 30, 2017.
No amortization was recorded on the Patent Application Rights to September 30, 2017.
Note 5. Credit Facility
On June 16, 2016, the Company executed a line of credit arrangement for an amount of up to $250,000 with Pleasants County Bank, West Virginia. Pursuant to the terms of the line of credit, interest will accrue on the amount of credit outstanding at a rate of 1.5% above the prime rate adjusted monthly. The Company’s President and CEO pledged personal assets to secure the line of credit and the Company pledged its
patent rights in the provisional patent application numbered 62287857, dated January 21, 2016, “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells”.
As at December 31, 2016, the balance outstanding was $nil. As of September 30, 2017, the line of credit was canceled and the pledged assets were released.
Note 6. Common Shares Issued for Services
During the nine month periods ended September 30, 2017 and 2016, the Company issued shares of common stock for services and other value rendered as follows:
2017
|
Number
of Shares
|
|
Value
per Share
|
|
Total
|
|
|
|
|
|
|
|
|
January - September 2017
|
|
|
-
|
|
|
$
|
-
|
|
|
$
|
-
|
|
|
|
|
-
|
|
|
|
|
|
|
$
|
-
|
|
2016
|
|
Number
of Shares
|
|
|
Value
per Share
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
March 2016
|
|
|
100,000
|
|
|
$
|
0.07
|
|
|
$
|
7,000
|
|
|
|
|
100,000
|
|
|
|
|
|
|
$
|
7,000
|
|
Note 7. Stock Options
On December 30, 2016, the Board of Directors of the Company adopted the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”). The Board of Directors adopted the 2017 Plan as it anticipates utilizing equity compensation as part of its ongoing standard corporate operations and in connection with its contemplated activities going forward.
The aggregate number of shares that may be issued under the 2017 Plan is 30,000,000 shares subject to adjustment as provided therein. The 2017 Plan includes two types of options. Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended are referred to as incentive options. Options which are not intended to qualify as incentive options are referred to as non-qualified options.
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 7. Stock Options
(cont’d)
As of September 30, 2017, 27,200,000 options and no shares of common stock have been granted under the 2017 Plan.
The 2017 Plan is administered by the Board of Directors, or a committee appointed by the Board of Directors. In addition to determining who will be granted options or stock bonuses, the committee has the authority and discretion to determine when options and bonuses will be granted and the number of options and bonuses to be granted. The committee also may determine a vesting and/or forfeiture schedule for bonuses and/or options granted, the time or times when each option becomes exercisable, the duration of the exercise period for options and the form or forms of the agreements, certificates or other instruments evidencing grants made under the 2017 Plan. The committee may determine the purchase price of the shares of common stock covered by each option. The committee also may impose additional conditions or restrictions not inconsistent with the provisions of the 2017 Plan. The committee may adopt, amend and rescind such rules and regulations as in its opinion may be advisable for the administration of the 2017 Plan.
In the event that a change, such as a stock split, is made in the Company’s capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested bonuses and in the exercise price and in the number of shares subject to each outstanding option. The committee also may make provisions for adjusting the number of bonuses or underlying outstanding options in the event the Company effects one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of its outstanding common stock. Options and bonuses may provide that in the event of the dissolution or liquidation of the Company, a corporate separation or division or the merger or consolidation of the Company, the holder may exercise the option on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the committee may provide that each option granted under the 2017 Plan shall terminate as of a date fixed by the committee.
The exercise price of any option granted under the 2017 Plan must be no less than 100% of the “fair market value” of the Company’s common stock on the date of grant. The exercise period of any option shall not exceed ten years from the date of grant of the option. Any incentive stock option granted under the 2017 Plan to a person owning more than 10% of the total combined voting power of the common stock must be at a price of no less than 110% of the fair market value per share on the date of grant and the term shall be for no more than five years.
Stock option transactions are summarized as follows:
|
|
Number of
Stock Options
|
|
|
Weighted Average
Exercise Price
|
|
|
Weighted Average
Fair Value
|
|
|
Weighted Average
Remaining Life
|
|
|
|
|
|
|
$
|
|
|
$
|
|
|
(Years)
|
|
Outstanding, December 31, 2016
|
|
|
28,900,000
|
|
|
|
0.06
|
|
|
|
0.04
|
|
|
|
|
Options granted
|
|
|
27,200,000
|
|
|
|
0.05
|
|
|
|
0.03
|
|
|
|
|
Options expired
|
|
|
(1,000,000
|
)
|
|
|
0.10
|
|
|
|
0.03
|
|
|
|
|
Outstanding, September 30, 2017
|
|
|
55,100,000
|
|
|
|
0.06
|
|
|
|
0.04
|
|
|
|
2.77
|
|
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 7. Stock Options
(cont’d)
The fair values of the stock options granted during the nine month periods ended June 30, 2017 and 2016 were estimated using the Black-Scholes Option Pricing Model. The weighted average assumptions used in the pricing model for these options are as follows:
|
September 30, 2017
|
September 30, 2016
|
Risk-free interest rate
|
1.05%
|
0.56%
|
Dividend yield
|
0.00%
|
0.00%
|
Expected stock price volatility
|
125.00%
|
125.00%
|
Expected forfeiture rate
|
0.00%
|
0.00%
|
Expected life
|
3.46 years
|
3.94 years
|
The following non-qualified stock options were outstanding and exercisable at September 30, 2017:
Expiry date
|
|
Exercise Price
|
|
|
Number of Options
Outstanding
|
|
|
Number of
Options
Exercisable
|
|
|
|
$
|
|
|
|
|
|
|
|
February 25, 2020
|
|
|
0.04
|
|
|
|
2,000,000
|
|
|
|
-
|
|
February 24, 2018
|
|
|
0.05
|
|
|
|
1,000,000
|
|
|
|
1,000,000
|
|
February 25, 2020
|
|
|
0.04
|
|
|
|
4,000,000
|
|
|
|
4,000,000
|
|
February 28, 2020
|
|
|
0.04
|
|
|
|
5,000,000
|
|
|
|
5,000,000
|
|
June 30, 2018
|
|
|
0.10
|
|
|
|
600,000
|
|
|
|
600,000
|
|
December 31, 2019
|
|
|
0.08
|
|
|
|
15,000,000
|
|
|
|
15,000,000
|
|
October 05, 2018
|
|
|
0.08
|
|
|
|
300,000
|
|
|
|
300,000
|
|
December 31, 2020
|
|
|
0.05
|
|
|
|
16,200,000
|
|
|
|
12,150,000
|
|
August 31, 2021
|
|
|
0.06
|
|
|
|
11,000,000
|
|
|
|
-
|
|
|
|
|
|
|
|
|
55,100,000
|
|
|
|
38,050,000
|
|
As at September 30, 2017, the aggregate intrinsic value of the Company’s stock options is $392,000 (December 31, 2016 – $110,000). The weighted average fair value of stock options granted during the nine month period ended September 30, 2017 is $0.03 (2016 - $0.05).
Warrant transactions for the nine month period ended September 30, 2017 are summarized as follows:
|
|
Number of
Warrants
|
|
|
Weighted
Average Exercise
Price
|
|
Balance, December 31, 2016 and September 30, 2017
|
|
|
6,500,000
|
|
|
$
|
0.11
|
|
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 8. Warrants
(cont’d)
The following warrants were outstanding and exercisable as at September 30, 2017:
Number of Warrants
|
|
|
Exercise Price ($)
|
|
Expiry Date
|
|
500,000
|
|
|
|
0.25
|
|
November 8, 2018
|
|
6,000,000
|
|
|
|
0.10
|
|
April 22, 2020
|
|
6,500,000
|
|
|
|
|
|
|
Note 9. Stockholders’ Equity
The Company is authorized to issue 400,000,000 (December 31, 2016 – 400,000,000) shares of $0.0000053 par value common stock. Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of September 30, 2017 (December 31, 2016 - $nil).
During the nine month period ended September 30, 2017, the Company:
a)
|
Issued 8,000,000 shares of common stock to investors (which included both the President and CEO as well as the CFO of the Company) at $0.04 for gross proceeds of $320,000.
|
b)
|
Issued 4,400,000 shares of common stock to investors at $0.05 for gross proceeds of $220,000.
|
Note 10. Related Party Transactions and Balances
During the nine month period ended September 30, 2016, the Company:
|
a)
|
Entered into a consulting agreement with an effective date of January 1, 2016 with the Company’s President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company’s President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control. In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of an Application Sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement. Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options are fully vested as at September 30, 2017.
|
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 10. Related Party Transactions and Balances
(cont’d)
|
b)
|
Entered into a consulting agreement with an effective date of January 1, 2016 with the Company’s CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company’s CFO $36,000 if terminated without cause or $72,000 upon termination due to a change of control event. Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7).
The options are fully vested as at September 30, 2017. A total of $54,000 was paid to the Company’s CFO during the nine month period ended September 30, 2016 and is included in professional fees.
|
|
c)
|
Entered into a directorship agreement with an effective date of January 1, 2016 with a director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options are fully vested as at September 30, 2017.
|
|
d)
|
Recognized $407,780 in share-based compensation associated with stock options granted to key management personnel.
|
During the nine months ended September, 30, 2017, the Company:
a)
|
Entered into a consulting agreement with an effective date of January 1, 2017 with the Company’s President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2017. The agreement also stipulates a termination fee that would pay the Company’s President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control. In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of a sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement. Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note7). The options vest in equal installments on a quarterly basis beginning March 31, 2017. On September 1, 2017 the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew. The consulting agreement was also amended
to grant an additional 5,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7). The options vest quarterly in equal installments beginning December 31, 2017.
|
b)
|
Entered into a consulting agreement with an effective date of January 1, 2017 with the Company’s CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2017. The agreement also stipulates a termination fee that would pay the Company’s CFO $72,000 per year of service (including the pro-rata amount for partial years of service) if terminated without cause or upon termination due to a change of control event. Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7). The options vest in equal installments on a quarterly basis beginning March 31, 2017. A total of $54,000 was paid to the Company’s CFO during the period ended September 30, 2017 and is included in professional fees.
|
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 10. Related Party Transactions and Balances
(cont’d)
c)
|
Entered into a directorship agreement with an effective date of January 1, 2017 with a director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7). The options vest in equal installments on a quarterly basis beginning March 31, 2017. On September 1, 2017 the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew. The consulting agreement was also amended to grant an additional 1,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7). The options vest quarterly in equal installments beginning December 31, 2017.
|
d)
|
Recognized $297,412 in share-based compensation associated with stock options granted to key management personnel.
|
As at September 30, 2017 and December 31, 2016, the following amounts are due to related parties:
|
|
|
September 30,
2017
|
|
|
December 31,
2016
|
|
Clarence Smith (CEO)
|
Accounts payable and accrued liabilities
|
|
$
|
-
|
|
|
$
|
81
|
|
Amounts included in accounts payable and accrued liabilities are non-interest bearing, unsecured and repayable on demand.
Note 11.
Commitments and Contingency
As at September 30, 2017, the Company has the following commitments:
a)
|
Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $7,000 per month for providing research and development services. Pursuant to the agreement, the consultant was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7). The options vest in equal installments on a quarterly basis beginning March 31, 2017. On September 1, 2017 the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew. The consulting agreement was also amended to grant an additional 5,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7). The options vest quarterly in equal installments beginning December 31, 2017.
|
b)
|
Entered into a consulting agreement for business development services effective January 1, 2017. The consultant was granted 1,200,000 stock options exercisable into common shares of the Company at a price of $0.05 per share until December 31, 2020 (Note 7). The options vest in equal installments on a quarterly basis beginning March 31, 2017.
|
c)
|
Entered into a Collaborative Research Agreement (the “CREA”) effective May 31, 2016 with The University of British Columbia (“UBC”) for a term of 2 years. Pursuant to the CREA, the Company paid a total of CAD $169,000 ($131,448) in advance for services to be provided by UBC in the first year, and paid an additional CAD $201,500 ($146,585) during the nine month period ended September 30, 2017, in advance of services to be provided by UBC in the second year. The CREA can be terminated by either party with 30 days’ written notice. As at September 30, 2017, a total of $97,723 is included in prepaid expenses and deposits (December 31, 2016 - $54,770).
|
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 11.
Commitments and Contingency
(cont’d)
d)
|
Entered into a consulting agreement effective March 1, 2015, whereby the Company would pay the consultant $2,700 per month for an initial term of 1 year, continued on a year-to-year basis thereafter unless otherwise terminated by either party with at least 30 days’ notice, for providing public relations services. The consultant is also entitled to 400,000 shares of common stock, which will be issued at a rate of 25% (100,000 shares) every 3 months over the term of the agreement (100,000 shares issued during the nine month period ended September 30, 2016 (Note 6)). The consultant was also issued 1,000,000 stock options on signing during the year ended December 31, 2015, with each stock option exercisable into a common share at a price of $0.10. The stock options expired March 12, 2016.
|
e)
|
Entered into a royalty agreement with the Governors of the University of Alberta (the “University”) whereby the University had developed certain intellectual property (the “Additional Patent Rights”) in conjunction with and by permission of the Company employing patented intellectual property of the Company. The agreement assigns the Additional Patent Rights to the Company in return for 5% of any future gross revenues (the “Royalty”) derived from products arising from the Patent Rights.
|
f)
|
Entered into a consulting agreement effective May 1, 2015, whereby the Company would pay the consultant $4,000 per month for an initial term of 1 year, continued on a year-to-year basis thereafter unless otherwise terminated by either party with at least 30 days’ notice for providing research and development services. During the nine month period ended September 30, 2017 the contract was revised whereby the Company would pay the consultant CAD $4,000 per month retroactively beginning January 1, 2017.
|
g)
|
Entered into a Material Transfer Agreement effective March 31, 2017 with Proactive Immune Sciences Corporation (“Proactive”) for a term of 1 year. The Company will furnish AAGP™ at no cost to Proactive so that they may test and evaluate AAGP™ for possible use in Immune Cell Banking.
|
The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, “Report of Foreign Bank and Financial Accounts” (“FBARs”). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs. Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no underreported tax liabilities. The Company may be liable for civil penalties for certain tax years in an indeterminate amount for not complying with the FBAR reporting and recordkeeping requirements. No claim has been asserted by the U.S. Internal Revenue Service; before any claim is expressly asserted the Company intends to cooperate with the Internal Revenue Service to minimize any liability. The Company is unable to determine the amount of any penalties that may be assessed at this time.
PROTOKINETIX, INCORPORATED
(A Development Stage Company)
NOTES TO FINANCIAL STATEMENTS
September 30, 2017
(Unaudited)
Note 12. Subsequent Event
Subsequent to the nine month period ended September 30, 2017, the Company:
a)
|
Entered into two Promissory Notes (the “Notes”) with the Company’s President and CEO whereby a total of $116,000 was loaned to the Company. The Notes bear interest at a rate of 8% per annum, are unsecured and are repayable on demand. The funds from these Notes will be used to make payment under the Settlement Agreement referred to below.
|
b)
|
Entered into a Settlement Agreement with the Company’s CFO on November 3, 2017 whereby she will leave her position as CFO effective upon the filing of the Company’s quarterly report for the nine month period ended September 30, 2017. Pursuant to the Settlement Agreement, the Company will pay the former CFO $6,000 for December 2017 consulting services (Note 10) and $110,000 in exchange for the return of stock options to purchase up to 12,000,000 shares of the Company’s common stock currently held by the CFO, which will be subsequently cancelled.
|